Adverum Biotechnologies is creating one-time gene therapies for patients with ocular and rare diseases. These gene therapies provide durable expression of therapeutic proteins that are lacking in diseased patients. To identify effective vectors to deliver the gene therapies, Adverum is using multi-step directed evolution that screens millions of different Adeno-associated viruses’ (AAVs) capsid genes for novel properties such as cell type specificity. Following novel vector discovery, selected optimized AAVs can be produced using Adverum’s highly scalable manufacturing process. Adverum is advancing a pipeline of gene therapies for ocular diseases such as ADVM-022 for age-related macular degeneration which has entered clinical trials.

<p>Adverum Biotechnologies is creating one-time gene therapies for patients with ocular and rare diseases. These gene therapies provide durable expression of therapeutic proteins that are lacking in diseased patients. To identify effective vectors to deliver the gene therapies, Adverum is using multi-step directed evolution that screens millions of different Adeno-associated viruses’ (AAVs) capsid genes for novel properties such as cell type specificity. Following novel vector discovery, selected optimized AAVs can be produced using Adverum’s highly scalable manufacturing process. Adverum is advancing a pipeline of gene therapies for ocular diseases such as ADVM-022 for age-related macular degeneration which has entered clinical trials.</p>


Adverum Biotechnologies

Adverum Biotechnologies

Short description:

Drug notes:

Long description:

Jobs: